SciSparc (SPRC) Common Equity (2016 - 2025)
SciSparc (SPRC) posted Common Equity of $5.1 million for Q4 2025, up 758.18% sequentially from -$782000.0 in Q2 2025, and down 42.42% YoY from $8.9 million in Q4 2024.
SciSparc (SPRC) Common Equity (2016 - 2025) Analysis & Trends
SciSparc has reported Common Equity for 10 years, with the latest figure at $5.1 million in Q4 2025.
- Quarterly Common Equity fell 42.42% year-over-year to $5.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.1 million (down 42.42% YoY) and the FY2025 annual result came in at $5.1 million, down 42.42% from the prior year.
- Common Equity climbed to $5.1 million in Q4 2025 per SPRC's latest filing, from -$782000.0 in the prior quarter.
- Over five years, Common Equity peaked at $9.6 million in Q4 2023 and troughed at -$782000.0 in Q2 2025.
- A 5-year average of $6.4 million and a median of $6.9 million in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2021 and 2025: Common Equity soared 1191.8% in 2021, then plunged 111.3% in 2025.
- Over 5 years, Common Equity stood at $8.1 million in 2021, then dropped by 20.78% to $6.4 million in 2022, then surged by 48.66% to $9.6 million in 2023, then dropped by 6.76% to $8.9 million in 2024, then slumped by 42.42% to $5.1 million in 2025.
- According to Business Quant data, Common Equity over the past three periods registered $5.1 million, -$782000.0, and $8.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | SciSparc | 836,385.99 | 836,385.99 | - | 5.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.15 Mn |
| Jun 30, 2025 | -782,000.00 |
| Dec 31, 2024 | 8.94 Mn |
| Jun 30, 2024 | 6.92 Mn |
| Dec 31, 2023 | 9.59 Mn |
| Jun 30, 2023 | 6.78 Mn |
| Dec 31, 2022 | 6.45 Mn |
| Sep 30, 2022 | 8.35 Mn |
| Jun 30, 2022 | 3.04 Mn |
| Dec 31, 2021 | 8.14 Mn |
| Jun 30, 2021 | 7.59 Mn |
| Dec 31, 2020 | 1.43 Mn |
| Jun 30, 2020 | -695,000.00 |
| Dec 31, 2019 | -51.71 Mn |
| Jun 30, 2019 | -742,000.00 |
| Mar 31, 2019 | -850,000.00 |
| Dec 31, 2018 | 77,000.00 |
| Sep 30, 2018 | 3.61 Mn |
| Jun 30, 2018 | 5.15 Mn |
| Mar 31, 2018 | 6.50 Mn |